enter

Genetic Analysis Systems Enter the Clinical Mainstream

Like many other diagnostic regimes that were previously restricted to large specialty laboratories, genetic analysis is entering the clinical mainstream. Smaller, simpler analyzer systems are now suitable and affordable for hospital or large physicians group labs, while some genetic test kits are becoming available for primary point of care locations such as clinics and physician offices.<...

Annual Meeting of the Consortium of Multiple Sclerosis Centers Focuses on the Challenges of Care and Research in Multiple Sclerosis

WASHINGTON, June 01, 2007 /PRNewswire/ -- The annual meeting ofthe Consortium of Multiple Sclerosis Centers (CMSC), the largestmeeting devoted to the comprehensive care and science of multiplesclerosis (MS), is underway in the nation's capital today. Multiplesclerosis, a disease of the central nervous system that affects400,000 people in the United States, challenges patients, carepartne...

Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants

Study released at the Pediatric Academic Societies' Annual MeetingThis Month in Toronto Shows That Switching to Masimo SET PulseOximetry Technology Can Reduce the Risk Associated with ROP by 40% IRVINE, Calif., May 30, 2007 /PRNewswire/ -- Masimo, theinventor of Pulse CO-Oximetry and Read-Through Motion and LowPerfusion pulse oximetry, reported that a new independent studypresented at the...

Nuvelo Announces Publication of NU206 Study Results in Gastroenterology

SAN CARLOS, Calif, April 11, 2007 /PRNewswire-FirstCall/ --Nuvelo, Inc. today announced the publication of data from a studyof NU206 (R-Spondin1), a secreted protein currently in preclinicaldevelopment, showing that it acts as a specific and potentstimulator of gastrointestinal (GI) epithelial cells. Thisepithelial lining is damaged in patients with inflammatory bowelconditions, includin...

GSK and Adolor Announce Preliminary Results from Phase 3 Safety Study of Alvimopan (Entereg/Entrareg)

LONDON & EXTON, Pa.--(BUSINESS WIRE)--Apr 9, 2007 -GlaxoSmithKline (LSE and NYSE:GSK) and Adolor Corporation(Nasdaq:ADLR) today announced data from Study 767905/014 andprovided an update on the clinical development program foralvimopan (Entereg/Entrareg(R)). Study 014, a Phase 3, double blind, placebo-controlled (12month) study, was designed to evaluate the long-term safety andtolera...

M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data at the AACR Annual Meeting

TSX: CTI OTCBB: CHKT VANCOUVER, April 02, 2007 /PRNewswire-FirstCall/ - ChemokineTherapeutics Corp. (the "Company") , a biotechnology companydeveloping chemokine-based therapies to treat cancer, blooddisorders, and vascular diseases, today announced that theUniversity of Texas M. D. Anderson Cancer Center's abstract,"Inhibition of primary growth and distant metastasis with a CXCR4antagon...